Cargando…
Resistance to kinase inhibition through shortened target engagement
Imatinib, a selective inhibitor of the breakpoint cluster region (BCR)-ABL kinase, is the poster child for targeted cancer therapeutics. However, its efficacy is limited by resistance mutations. Using a quantitative bioluminescence resonance energy transfer assay in living cells, we identified ABL k...
Autores principales: | Rangwala, Aziz M., Berger, Benedict-Tilman, Robers, Matthew B., Knapp, Stefan, Seeliger, Markus A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890393/ https://www.ncbi.nlm.nih.gov/pubmed/35252553 http://dx.doi.org/10.1080/23723556.2022.2029999 |
Ejemplares similares
-
A new “angle” on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition
por: Meyerowitz, Justin G, et al.
Publicado: (2015) -
Single tracer-based protocol for broad-spectrum kinase profiling in live cells with NanoBRET
por: Robers, Matthew B., et al.
Publicado: (2021) -
Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
por: Benes, Cyril H
Publicado: (2015) -
Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition
por: McQuade, Jennifer L, et al.
Publicado: (2015) -
Itraconazole perturbs colorectal cancer dormancy through SUFU-mediated WNT inhibition
por: Popova, Semiramis A., et al.
Publicado: (2018)